Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation

Fumihiro Shoji, Gouji Toyokawa, Noboru Harada, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Tatsuro Okamoto, Yuji Soejima, Tomoharu Yoshizumi, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

Background: De novo malignancy, including primary lung cancer, is one of the limitations to long-term survival after liver transplantation. The purpose of this study was to describe patients who developed de novo lung cancer after living-donor liver transplantation (LDLT) and investigate their clinicopathological features as well as the feasibility of surgical resection. Patients and Methods: We investigated 554 patients who underwent LDLT. Results: De novo lung cancer after LDLT was observed in five (0.9%) out of 554 studied patients: four men and one woman, aged 61-78 years (mean=67 years). All four men had a smoking history. Clinical stages of de novo lung cancer were stage IA in three patients, and stage IB and IV in one patient each. Three out of five patients underwent pulmonary lobectomy and pathological stage was IA in two patients and IIA in one. All patients who underwent surgery stopped immunosuppressive therapy 1 day preoperatively and restarted on postoperative day 1. There were no serious postoperative complications. All three patients are still alive without any recurrence, with survival ranging from 8 to 29 months, with an average of 16.3 months after diagnosis of lung cancer. Conclusion: Although the study population was small, these results suggest that pulmonary lobectomy of de novo lung cancer after LDLT, even under immunosuppressive conditions, is a feasible procedure and may yield a survival benefit.

Original languageEnglish
Pages (from-to)2619-2623
Number of pages5
JournalAnticancer research
Volume37
Issue number5
DOIs
Publication statusPublished - May 2017

Fingerprint

Liver Neoplasms
Liver Transplantation
Lung Neoplasms
Living Donors
Immunosuppressive Agents
Survival
Lung
Smoking
History
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation. / Shoji, Fumihiro; Toyokawa, Gouji; Harada, Noboru; Itoh, Shinji; Harimoto, Norifumi; Ikegami, Toru; Okamoto, Tatsuro; Soejima, Yuji; Yoshizumi, Tomoharu; Maehara, Yoshihiko.

In: Anticancer research, Vol. 37, No. 5, 05.2017, p. 2619-2623.

Research output: Contribution to journalArticle

Shoji, Fumihiro ; Toyokawa, Gouji ; Harada, Noboru ; Itoh, Shinji ; Harimoto, Norifumi ; Ikegami, Toru ; Okamoto, Tatsuro ; Soejima, Yuji ; Yoshizumi, Tomoharu ; Maehara, Yoshihiko. / Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation. In: Anticancer research. 2017 ; Vol. 37, No. 5. pp. 2619-2623.
@article{1857f94fa18d4860bb379bcb7369e3f1,
title = "Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation",
abstract = "Background: De novo malignancy, including primary lung cancer, is one of the limitations to long-term survival after liver transplantation. The purpose of this study was to describe patients who developed de novo lung cancer after living-donor liver transplantation (LDLT) and investigate their clinicopathological features as well as the feasibility of surgical resection. Patients and Methods: We investigated 554 patients who underwent LDLT. Results: De novo lung cancer after LDLT was observed in five (0.9{\%}) out of 554 studied patients: four men and one woman, aged 61-78 years (mean=67 years). All four men had a smoking history. Clinical stages of de novo lung cancer were stage IA in three patients, and stage IB and IV in one patient each. Three out of five patients underwent pulmonary lobectomy and pathological stage was IA in two patients and IIA in one. All patients who underwent surgery stopped immunosuppressive therapy 1 day preoperatively and restarted on postoperative day 1. There were no serious postoperative complications. All three patients are still alive without any recurrence, with survival ranging from 8 to 29 months, with an average of 16.3 months after diagnosis of lung cancer. Conclusion: Although the study population was small, these results suggest that pulmonary lobectomy of de novo lung cancer after LDLT, even under immunosuppressive conditions, is a feasible procedure and may yield a survival benefit.",
author = "Fumihiro Shoji and Gouji Toyokawa and Noboru Harada and Shinji Itoh and Norifumi Harimoto and Toru Ikegami and Tatsuro Okamoto and Yuji Soejima and Tomoharu Yoshizumi and Yoshihiko Maehara",
year = "2017",
month = "5",
doi = "10.21873/anticanres.11608",
language = "English",
volume = "37",
pages = "2619--2623",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation

AU - Shoji, Fumihiro

AU - Toyokawa, Gouji

AU - Harada, Noboru

AU - Itoh, Shinji

AU - Harimoto, Norifumi

AU - Ikegami, Toru

AU - Okamoto, Tatsuro

AU - Soejima, Yuji

AU - Yoshizumi, Tomoharu

AU - Maehara, Yoshihiko

PY - 2017/5

Y1 - 2017/5

N2 - Background: De novo malignancy, including primary lung cancer, is one of the limitations to long-term survival after liver transplantation. The purpose of this study was to describe patients who developed de novo lung cancer after living-donor liver transplantation (LDLT) and investigate their clinicopathological features as well as the feasibility of surgical resection. Patients and Methods: We investigated 554 patients who underwent LDLT. Results: De novo lung cancer after LDLT was observed in five (0.9%) out of 554 studied patients: four men and one woman, aged 61-78 years (mean=67 years). All four men had a smoking history. Clinical stages of de novo lung cancer were stage IA in three patients, and stage IB and IV in one patient each. Three out of five patients underwent pulmonary lobectomy and pathological stage was IA in two patients and IIA in one. All patients who underwent surgery stopped immunosuppressive therapy 1 day preoperatively and restarted on postoperative day 1. There were no serious postoperative complications. All three patients are still alive without any recurrence, with survival ranging from 8 to 29 months, with an average of 16.3 months after diagnosis of lung cancer. Conclusion: Although the study population was small, these results suggest that pulmonary lobectomy of de novo lung cancer after LDLT, even under immunosuppressive conditions, is a feasible procedure and may yield a survival benefit.

AB - Background: De novo malignancy, including primary lung cancer, is one of the limitations to long-term survival after liver transplantation. The purpose of this study was to describe patients who developed de novo lung cancer after living-donor liver transplantation (LDLT) and investigate their clinicopathological features as well as the feasibility of surgical resection. Patients and Methods: We investigated 554 patients who underwent LDLT. Results: De novo lung cancer after LDLT was observed in five (0.9%) out of 554 studied patients: four men and one woman, aged 61-78 years (mean=67 years). All four men had a smoking history. Clinical stages of de novo lung cancer were stage IA in three patients, and stage IB and IV in one patient each. Three out of five patients underwent pulmonary lobectomy and pathological stage was IA in two patients and IIA in one. All patients who underwent surgery stopped immunosuppressive therapy 1 day preoperatively and restarted on postoperative day 1. There were no serious postoperative complications. All three patients are still alive without any recurrence, with survival ranging from 8 to 29 months, with an average of 16.3 months after diagnosis of lung cancer. Conclusion: Although the study population was small, these results suggest that pulmonary lobectomy of de novo lung cancer after LDLT, even under immunosuppressive conditions, is a feasible procedure and may yield a survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=85019125465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019125465&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11608

DO - 10.21873/anticanres.11608

M3 - Article

C2 - 28476836

AN - SCOPUS:85019125465

VL - 37

SP - 2619

EP - 2623

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -